×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Chronic Pain | migraine | drug | succeeds | late-stage | study

Migraine Drug Succeeds in Late-Stage Study

Migraine Drug Succeeds in Late-Stage Study
(Copyright iStock)

Wednesday, 31 May 2017 08:45 AM

Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine met the main goal in a late-stage study.

Patients treated with the drug, fremanezumab, experienced a statistically significant reduction in the number of monthly headache days over the 12-week period for both monthly and quarterly dosing regimens, the company said.

© 2021 Thomson/Reuters. All rights reserved.


Health-News
Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine met the main goal in a late-stage study.Patients treated with the drug, fremanezumab, experienced a statistically significant reduction in the number of monthly headache days over...
migraine, drug, succeeds, late-stage, study
53
2017-45-31
Wednesday, 31 May 2017 08:45 AM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved